4 ms·
I wonder if this drop can be attributed to the approval of pembroluzimab? Our oncologists speak highly of it and it got to market around the mentioned time peri
by markus92 7y ago
I wonder if this drop can be attributed to the approval of pembroluzimab? Our oncologists speak highly of it and it got to market around the mentioned time period
- mrosett 7y agoAbsolutely. They mention immunotherapy in the article, and pembro (aka Keytruda) is the best-selling drug in that class. Another big one that was introduced around the same time is nivolumab (aka Opdivo). Immunotherapy has really transformed certain parts of oncology (including melanoma, which they mention in the article as well), which is why some of the foundational researchers won the Nobel last year.
- mamp 7y agoI think it’s a combination of immunotherapy for melanoma, bladder, renal cell and improved targeted therapy in certain types of lung adenocarcinoma.